Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 26, 2026Current Cancer Drug Targets

Anticancer Effect and Mechanism of Novel c-Myc Inhibitor BP1 onHepatocellular Carcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

SCShengkun CaoQYQingqing YangWXWangwei Xu

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates anticancer effects of BP1 in hepatocellular carcinoma, suggesting promising therapeutic potential.

Key Points

  • This study aims to assess the anticancer activity and mechanisms of the c-Myc inhibitor BP1 in hepatocellular carcinoma.
  • BP1 was synthesized as a novel small-molecule inhibitor targeting c-Myc.
  • Cell viability and migration were evaluated using MTT, colony formation, wound-healing, and Transwell assays in Huh7 and HepG2 cell lines.
  • Western blotting and qPCR assessed the effects of BP1 on c-Myc protein stability and downstream targets.
  • BP1 treatment reduced cell viability and clonogenic capacity by X% (exact value not given).
  • BP1 significantly increased apoptosis as assessed by Annexin V/PI flow cytometry (exact percentage not provided).
  • Pharmacokinetic analysis indicated rapid systemic clearance and short plasma half-life of BP1.

Cite This Study

Cao et al. (2026) studied this question.

synapsesocial.com/papers/6a3e169f030ad1a9b30906bahttps://doi.org/10.2174/0115680096444603260224040327
View Full Paper
Ask AI
Bookmark
Share